Join
Live feed
·
INSIDERFilingvia Quantisnow
Y-mAbs Therapeutics Inc. logo

Director Tyagi Ashu was granted 3,495 shares, increasing direct ownership by 150% to 5,825 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
YMAB· Y-mAbs Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track YMAB (Y-mAbs Therapeutics Inc.) and more on Quantisnow.